Substance Use Disorder Drug Pipeline — PatSnap Eureka
Substance Use Disorder Drug Pipeline: OUD, AUD, StUD & CUD
A research-driven overview of pharmacological and emerging therapeutic modalities across four primary SUD indications — from approved MOUD therapies to preclinical D3R compounds, CB1R modulators, psychedelics, and genomics-guided precision medicine approaches.
SUD Pipeline Landscape: Four Indications, Distinct Maturity Levels
Substance use disorders are characterized by dysregulation of dopaminergic, glutamatergic, GABAergic, opioidergic, serotonergic, and endocannabinoid pathways. The life sciences innovation platform at PatSnap tracks research activity across all four major SUD subtypes.
Most Clinically Advanced Indication
Methadone (full µ-opioid agonist), buprenorphine/naloxone (partial agonist), and extended-release injectable naltrexone (antagonist) form the approved MOUD triad. Novel long-acting injectable and implantable buprenorphine formulations address adherence and diversion risks. NIH and NIDA-IRP are also advancing D3R-selective partial agonist (S)-ABS01-113 (EC₅₀ = 7.6 nM, 55% intrinsic efficacy) as a non-opioid pharmacotherapy in preclinical models.
3 approved agents · D3R preclinicalThree Approved Agents, Active Investigational Landscape
Disulfiram (aldehyde dehydrogenase inhibition), naltrexone (opioid receptor antagonist), and acamprosate (NMDA receptor modulator) are FDA-approved. Nalmefene holds European regulatory approval. Multiple off-label and investigational agents are under review including baclofen, gabapentin, topiramate, ondansetron, varenicline, and novel compounds such as PF-05190457, ibudilast, samidorphan, and oxytocin analogs — none with completed Phase 3 data per retrieved records.
3 FDA-approved · 10+ investigationalNo Approved Pharmacotherapy — Highest Unmet Need
No FDA-approved pharmacotherapy exists for cocaine or methamphetamine use disorder. Stimulant substitution strategies (high-dose methylphenidate, amphetamine) and modafinil show clinical trial evidence for reduced cravings and increased abstinence in cocaine use disorder. The ADHD-SUD comorbidity — linked by shared prefrontal hypoactivation and hyperactive phasic dopaminergic neurotransmission — is driving interest in methylphenidate as a transdiagnostic agent per Maastricht University research (2023).
0 approved · Investigational onlyNo Approved Drug — CBD & CB1R Modulators in Trials
No approved pharmacotherapy for CUD has been identified in any retrieved result. Placebo-controlled RCTs of synthetic THC for CUD withdrawal symptoms show reduction in withdrawal but not cannabis use cessation. CBD clinical trials are ongoing across ClinicalTrials.gov and EU registries. Neutral CB1R antagonists — designed to replace rimonabant without its psychiatric adverse effects — remain in preclinical development at NIDA-IRP.
0 approved · CBD RCTs ongoingKey Molecular Targets & Pipeline Signals
Visualising the pharmacological target landscape and therapeutic modality distribution across the SUD drug pipeline, derived from academic and clinical literature analysis.
Key Molecular Targets Across SUD Subtypes
Number of pharmacological modalities targeting each receptor system across OUD, AUD, StUD, and CUD — illustrating the breadth of neurobiological targets under investigation.
Therapeutic Modalities by Development Stage
Distribution of 9 identified SUD therapeutic modalities across development stages — from approved agents to preclinical candidates — illustrating where innovation is concentrated.
Nine Pharmacological Approaches Spanning the SUD Pipeline
The SUD drug pipeline spans a diverse set of mechanistic approaches. For OUD, opioid receptor agonist/antagonist pharmacotherapy remains the most evidence-dense modality. Methadone and buprenorphine maintenance therapies outperform psychosocial treatment alone, with novel long-acting delivery formulations addressing adherence and diversion risks associated with sublingual self-administration.
Dopamine D3 receptor (D3R) targeting represents the leading non-opioid pharmacotherapy strategy for both OUD and stimulant use disorder. NIDA-IRP preclinical data describe compound (S)-ABS01-113 as a potent (EC₅₀ = 7.6 nM), highly selective D3R partial agonist with 55% intrinsic efficacy, tested in animal models of opioid seeking. Wake Forest School of Medicine data describe broader D3R antagonist profiles in rodent reinstatement models of cocaine abuse.
For AUD and CUD, glutamate-targeting agents (ketamine, N-acetylcysteine) and CB1R modulators (neutral antagonists, CBD) are the most active investigational areas. Ketamine has been evaluated in seven completed human studies across alcohol, cocaine, heroin, and other SUD populations. CBD — with its FDA-approved (Epidiolex) regulatory status — is the most frequently investigated emerging candidate across multiple SUD subtypes, with clinical trial programs examining it for opioid craving reduction, AUD, CUD withdrawal, and tobacco cessation. Learn more about life sciences drug discovery intelligence at PatSnap.
Immunotherapy (anti-addiction vaccines) represents a mechanistically distinct approach targeting the drug molecule itself via hapten conjugation. Nicotine and cocaine vaccines have progressed to Phase 3 trials — neither is currently approved, with immunogenicity limitations identified as the primary obstacle. Novel design strategies include nanoparticle carriers, synthetic haptens, and novel adjuvants.
The psychedelic renaissance encompasses LSD, psilocybin, ketamine, ibogaine, MDMA, DMT, mescaline, and salvinorin A across multiple SUD subtypes. Evidence is characterized as preliminary and observational/early-phase clinical for most agents, proposed to act through serotonin 5-HT₂A receptor agonism and neuroplasticity promotion. WHO has classified SUDs as a global public health priority requiring novel treatment approaches.
Key Targets, Mechanisms, and SUD Indications
| Molecular Target | SUD Indication(s) | Key Agents / Findings | Stage | Lead Institution |
|---|---|---|---|---|
| µ-Opioid Receptor (OPRM1) | OUD | Methadone (full agonist), buprenorphine (partial agonist), naltrexone (antagonist). OPRM1 A118G variants linked to treatment response heterogeneity. | Approved | Rockefeller University; UPenn |
| Dopamine D3 Receptor (DRD3) | OUD, StUD | (S)-ABS01-113: EC₅₀ 7.6 nM, 55% intrinsic efficacy. Reduces cue-, drug-, and stress-induced reinstatement of opioid and cocaine seeking in animal models. | Preclinical | NIDA-IRP; Wake Forest SOM |
| CB1R / Endocannabinoid System | CUD, OUD, AUD | Neutral CB1R antagonists (next-gen rimonabant replacement); CBD (CB1R modulation, TRPV1 agonism, 5-HT₁A partial agonism, GPR55 antagonism); synthetic THC for CUD withdrawal. | Early Clinical | NIDA-IRP; Instituto de Salud Carlos III |
| NMDA Glutamate Receptor (GRIN family) | AUD, StUD, OUD, CUD | Acamprosate (AUD, approved). Ketamine evaluated in 7 completed human studies across alcohol, cocaine, heroin SUD populations. NAC restores glutamate homeostasis via xCT/SLC7A11 modulation. | Early Clinical | Medical Univ. South Carolina; Maj Institute |
| PPAR-α / PPAR-γ | AUD, OUD, Nicotine | Robust preclinical evidence for ethanol consumption reduction. Human evidence limited; no published human trials for AUD as of publication date. | Preclinical | University of Toronto |
| DARPP-32 (PPP1R1B) | Cross-SUD | Convergence node for dopaminergic and other signaling cascades across multiple substances. Proposed as pharmacological target; limited investigational compounds to date. | Preclinical | University of Nottingham |
Track Emerging SUD Targets with AI-Powered Literature Search
PatSnap Eureka monitors patent and academic literature across all molecular targets in real time.
Six Emerging Directions Shaping the SUD Pipeline
Retrieved results from multiple institutions signal convergent trends across all four SUD subtypes — from polysubstance use design challenges to genomics-guided precision medicine.
Transdiagnostic / Cross-SUD Pharmacological Targeting
The identification of shared genetic risk factors (PDE4B, general addiction-risk polygenic score) and common neurobiological mechanisms (glutamate dysregulation, dopamine D3R, DARPP-32) is driving interest in pan-SUD pharmacological strategies. Methylphenidate for ADHD-SUD comorbidity and NAC for multiple SUD subtypes reflect this transdiagnostic approach per Maastricht University (2023).
CBD as a Broad-Spectrum SUD Agent
CBD is the most frequently investigated emerging pharmacological candidate across multiple SUD subtypes in this dataset. Retrieved results describe clinical trial programs examining CBD for opioid craving reduction, alcohol use disorder, cannabis use disorder withdrawal, and tobacco cessation. The non-psychoactive, FDA-approved (Epidiolex) status provides a regulatory entry point.
Genomics-Driven Precision Medicine
Retrieved results from multiple large GWAS and pharmacogenomics studies signal movement toward polygenic risk score-guided treatment selection. The ASPIRE personalized medicine framework for CUD and other SUDs is described as a novel precision approach by the NIDA Clinical Trials Network (2014). PDE4B reached genome-wide significance in a GWAS of over 1 million subjects.
Pharmacotherapy + Psychosocial Combination as Standard of Care
Across all four SUD subtypes, retrieved results consistently frame pharmacological treatments as most effective when combined with behavioral interventions including motivational enhancement therapy, CBT, and contingency management. This is most strongly evidenced for OUD (MOUD + counseling) and AUD (naltrexone + behavioral therapy).
Where SUD Innovation Is Being Generated
All retrieved records in this dataset are academic literature — no patent assignees were identified. Innovation activity is predominantly literature-driven, concentrated in U.S. academic medical centers, government research institutes, and European research consortia.
NIDA Intramural Research Program (NIDA-IRP), Baltimore is the most active single contributor for molecular pharmacology in this dataset, with research on D3R-selective compounds, CB1R neutral antagonists, and CBD receptor mechanisms. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) contributes work on unmet clinical needs in AUD treatment. Track these research programs using PatSnap's IP analytics platform.
U.S. academic medical centers include Yale University School of Medicine (AUD, OUD, novel abuse-liability pharmacology), University of Pennsylvania (OUD treatment, cocaine use disorder), UCSF (intracellular signaling pathways for AUD), Medical University of South Carolina (ketamine and glutamate-targeting), Indiana University School of Medicine (GWAS of over 1 million subjects), and Wake Forest School of Medicine (D3R pharmacology for psychostimulant addiction).
European and Canadian institutions include Instituto de Salud Carlos III/RETICS (Spain) for ECS biomarkers and CBD, Maastricht University (Netherlands) for methylphenidate transdiagnostic approach, Aarhus University Centre for Alcohol and Drug Research (Denmark) for cannabinoid-based CUD treatment in youth populations, and CAMH Toronto and University of Toronto for PPAR agonists and CUD psychosocial treatment. EMA regulatory frameworks govern European approvals including nalmefene for AUD. See how leading life sciences organizations use PatSnap to monitor competitor research activity.
Substance Use Disorder Drug Pipeline — Key Questions Answered
Methadone (full µ-opioid agonist), buprenorphine and buprenorphine/naloxone (partial agonist), and extended-release injectable naltrexone (antagonist) are the established pharmacological backbone for OUD treatment. Retrieved results emphasize that extended treatment duration and co-administration with psychosocial support maximize efficacy.
No FDA-approved pharmacotherapy has been identified for stimulant use disorder in retrieved results. Retrieved results describe stimulant medications (methylphenidate, amphetamine) and modafinil as having clinical trial evidence for reduced cravings and increased abstinence specifically in cocaine use disorder.
CBD is the most frequently investigated emerging pharmacological candidate across multiple SUD subtypes in this dataset. Retrieved results describe clinical trial programs examining CBD for opioid craving reduction, alcohol use disorder, cannabis use disorder withdrawal, and tobacco cessation. The non-psychoactive, FDA-approved (Epidiolex) status of CBD provides a regulatory entry point.
Three FDA-approved agents for AUD are identified: disulfiram (aversive agent via aldehyde dehydrogenase inhibition), naltrexone (opioid receptor antagonist), and acamprosate (NMDA receptor modulator), with nalmefene additionally referenced under European regulatory approval. Retrieved results characterize these agents as modestly effective with limited uptake due to side effects and adherence challenges.
A shared genetic addiction risk factor has been identified in large-scale genome-wide association studies (GWAS) encompassing over 1 million subjects, with the PDE4B gene (dopamine regulation) reaching genome-wide significance as a cross-trait vulnerability locus.
Nicotine and cocaine vaccines have completed Phase 3 trials per retrieved results; neither is currently approved. Immunogenicity limitations are identified as the primary obstacle. Innovative design strategies in this dataset include nanoparticle carriers, synthetic haptens, and novel adjuvants to improve immunogenicity.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About SUD Pipeline DataAccelerate Your SUD Drug Discovery Research
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D across opioid, alcohol, stimulant, and cannabis use disorder pipelines.
References
- Newman et al. — A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder. NIDA-IRP (2022)
- Targeting the intracellular signaling "STOP" and "GO" pathways for the treatment of alcohol use disorders. UCSF, Department of Neurology (2018)
- A Pathway-Based Genomic Approach to Identify Medications: Application to Alcohol Use Disorder. University of Texas at Austin (2019)
- Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders. NIDA-IRP (2022)
- The treatment of cocaine use disorder. University of Pennsylvania (2019)
- Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. Indiana University School of Medicine (2022)
- Advances in the delivery of buprenorphine for opioid dependence. Icahn School of Medicine at Mount Sinai (2017)
- Advances in the treatment of opioid use disorders. University of Pennsylvania (2017)
- Current status of opioid addiction treatment and related preclinical research. Rockefeller University (2019)
- Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. Wake Forest School of Medicine (2015)
- Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Instituto de Salud Carlos III (2021)
- Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth? Aarhus University (2022)
- Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Medical University of South Carolina (2018)
- N-acetylcysteine in substance use disorder: a lesson from preclinical and clinical research. Maj Institute of Pharmacology, Polish Academy of Sciences (2021)
- Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders. University of Toronto (2020)
- A Review of Immunotherapeutic Approaches for Substance Use Disorders. VA Connecticut Healthcare System / Yale (2022)
- Classic and non-classic psychedelics for substance use disorder: A review. Universidade Federal de São Paulo (2022)
- Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders. Yale University School of Medicine (2022)
- Methylphenidate as a treatment option for substance use disorder: a transdiagnostic perspective. Maastricht University (2023)
- Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Women's Clinic Lucerne / Cantonal Hospital (2022)
- Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals. NIDA-IRP (2020)
- Exploring the Role of DARPP-32 in Addiction. University of Nottingham (2022)
- Bi-directional Acceleration of Alcohol Use and Opioid Use Disorder. Seton Hall University (2019)
- Synthesizing evidence on the impacts of COVID-19 regulatory changes on methadone treatment for opioid use disorder. NYU Grossman School of Medicine (2022)
- Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers. INSERM UMRS1144, Paris (2021)
- One Is Not Enough: Understanding and Modeling Polysubstance Use. Seattle Children's Research Institute (2020)
- Polysubstance use in the U.S. opioid crisis. NIDA (2020)
- Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Centre hospitalier de l'Université de Montréal (2015)
- ASPIRE Model for Treating Cannabis and Other Substance Use Disorders: A Novel Personalized-Medicine Framework. NIDA Clinical Trials Network (2014)
- World Health Organization (WHO) — Substance Use Disorders Global Health Data
- National Institute on Drug Abuse (NIDA) — Drug Use Statistics and Treatment Research
- European Medicines Agency (EMA) — Nalmefene and AUD Regulatory Information
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.